医药行业周报：拜耳Kerendia达到3期临床终点，计划递交监管申请

Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as Neutral [1][3]. Core Insights - The pharmaceutical sector showed a performance increase of +1.88% on August 6, 2024, outperforming the CSI 300 index by 1.89 percentage points, ranking 7th among 31 sub-industries in the Shenwan classification [4]. - Notable performers within the pharmaceutical sub-industries included vaccines (+2.54%), medical research outsourcing (+2.46%), and other biological products (+2.40%), while offline pharmacies (-0.38%) and blood products (+0.88%) lagged behind [4]. - Bayer announced that its FIC therapy Kerendia (Finerenone) achieved its primary endpoint in a Phase 3 clinical trial for heart failure patients, leading to plans for a regulatory submission to the FDA [5]. Summary by Sections Market Performance - On August 6, 2024, the pharmaceutical sector's performance was +1.88%, surpassing the CSI 300 index by 1.89 percentage points, with specific sub-industry performances highlighted [4]. Industry News - Bayer's Kerendia reached significant clinical trial milestones, prompting plans for regulatory discussions with the FDA [5]. Company News - Yifan Pharmaceutical received approval for Mesobam Injection from the National Medical Products Administration [6]. - Huahai Pharmaceutical announced the approval of Fumaric Acid Lupanatide Tablets and Vildagliptin Tablets [6]. - Renfu Pharmaceutical's subsidiary received approval for Omega-3 Fatty Acid Ethyl Ester Capsules [6]. - Fuyuan Pharmaceutical was granted approval for Agomelatine Tablets [6].